Document is current
Any future updates will be listed below
-
Authors
Ross, Ashley E.
Hurley, Paula J.
Tran, Phuoc T. http://orcid.org/0000-0002-0147-0376
Rowe, Steven P.
Benzon, Benjamin
Neal, Tanya O’
Chapman, Carolyn
Harb, Rana
Milman, Yelena
Trock, Bruce J.
Drake, Charles G.
Antonarakis, Emmanuel S.
-
Funding
Funding for this research was provided by:
Prostate Cancer Foundation
Merck
- License Information
-
More Information
Article History
Received: 5 June 2019
Revised: 30 July 2019
Accepted: 13 August 2019
First Online: 14 October 2019
Compliance with ethical standards
:
: AER has previously been a consultant for Healthtronics. PTT has grant support from Astellas Pharm., RefleXion Medical, Inc and Bayer Healthcare; and has consulted for RefleXion Medical, Inc. CGD acknowledges stock or ownership interests in Compugen, Harpoon, Kleo, Potenza, and Tizona Therapeutics, and has served as a consultant for Agenus, Dendreon, Janssen Oncology, Eli Lilly, Merck, AstraZeneca, MedImmune, Pierre Fabre, Genentech, and Genocea Biosciences. ESA is a paid consultant/advisor to Janssen, Astellas, Sanofi, Dendreon, Medivation, AstraZeneca, Clovis, and Merck; he has received research funding to his institution from Janssen, Johnson & Johnson, Sanofi, Dendreon, Genentech, Novartis, Tokai, Bristol Myers-Squibb, AstraZeneca, Clovis, and Merck; and he is the co-inventor of an AR-V7 biomarker technology that has been licensed to Qiagen. The other authors declare that they have no conflict of interest.
